

UMass Chan Medical School

eScholarship@UMassChan

UMass Center for Clinical and Translational
Science Research Retreat

2013 UMass Center for Clinical and
Translational Science Research Retreat

May 8th, 12:30 PM - 1:30 PM

A Multicenter Phase 2 Study Incorporating High-Dose Rituximab into the CODOX-M/IVAC Regimen for Untreated Burkitt's Lymphoma (BL): Examination of Correlative Serum and CSF Rituximab Levels

Andrew Evens

University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat



Part of the Hematology Commons, Hemic and Lymphatic Diseases Commons, Neoplasms Commons, Oncology Commons, Therapeutics Commons, and the Translational Medical Research Commons

Repository Citation

Evens A, Islam N, Carson K, Browning V, Nabhan C, Jovanovic B, Barr PM, Caimi P, Gregory SA, Kolesar JM, Gordon LI. (2013). A Multicenter Phase 2 Study Incorporating High-Dose Rituximab into the CODOX-M/IVAC Regimen for Untreated Burkitt's Lymphoma (BL): Examination of Correlative Serum and CSF Rituximab Levels. UMass Center for Clinical and Translational Science Research Retreat. <https://doi.org/10.13028/8dra-7662>. Retrieved from https://escholarship.umassmed.edu/cts_retreat/2013/posters/60

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/).

This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.

A Multicenter Phase 2 Study Incorporating High-Dose Rituximab into the CODOX-M/IVAC Regimen for Untreated Burkitt's Lymphoma (BL): Examination of Correlative Serum and CSF Rituximab Levels

Andrew M. Evens, DO, MSc¹, Islam, Nahida, MD¹, Kenneth Carson, MD², Victoria Browning, PhD³, Chadi Nabhan, MD, FACP⁴, Borko Jovanovic, PhD⁵, Paul M. Barr, MD⁶, Paolo Caimi, MD⁷, Stephanie A. Gregory, MD⁸, Jill M. Kolesar, PharmD³, Leo I. Gordon, MD⁹

¹Division of Hematology/Oncology, The University of Massachusetts, Worcester, MA; ²Division of Hematology/Oncology, Washington University, St. Louis, MO; ³School of Pharmacy, University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI; ⁴Oncology Specialists, S.C., Lutheran General Hospital Cancer Center, Park Ridge, IL; ⁵Department of Preventive Medicine, Northwestern University, Chicago, IL; ⁶Division of Hematology/Oncology, University of Rochester, Rochester, NY; ⁷Division of Hematology/Oncology, Case Western Reserve University, Cleveland, OH; ⁸Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL. ⁹Division of Hematology/Oncology, Northwestern University, Chicago, IL;

Background: Two-year survival rates for adult BL remain <60-65%. Furthermore, there is a paucity of data adding Rituximab to CODOX-M/IVAC therapy and virtually no data regarding the significance of serum or cerebrospinal fluid (CSF) levels.

Methods: Twenty-five BL patients were enrolled. Patients had low-risk (LR) or high-risk (HR) disease; LR patients received 3 CODOX-M cycles, while HR had 4 alternating CODOX-M/IVAC cycles (Mead et al. Blood 2009). Rituximab (500mg/m²) was given x 2 doses each cycle. Correlative analyses of paired serum and CSF Rituximab levels were obtained for cycles 1+3 at 24+72 hours.

Results: There were 20 HR and 5 LR patients and median age was 44 years (range, 23-70). 3 HR and 1 LR patient were HIV+, while 15% of HR patients had CNS disease. Additionally, 35% of HR patients had bulk >10 cm and 40% had bone marrow involvement. Myelosuppression and mucositis appeared comparable with prior CODOX-M/IVAC data. The overall remission rate after 2 cycles was 100% with 67% complete remission. At 34-month median follow-up, 2-year PFS and OS rates for all patients were 86% and 86%, respectively (LR 2-year PFS and OS: both 100%; HR 2-year PFS and OS: both 82%). Further, the 2-year PFS and OS for HR, HIV-negative patients were 91% and 91%, respectively (disease-specific survival 100%). Two patients died from progressive disease (both HIV+ HR). The median serum and CSF rituximab levels for these patients were compared with patients without relapse (**Table 1**). Interestingly, cycle 1, 24-hour serum Rituximab levels were significantly higher among patients without relapse compared with the two patients who relapsed/died (P=0.042). Cycle 3, 24-hour Rituximab levels were of borderline significance (P=0.06).

Conclusions: The integration of Rituximab into CODOX-M/IVAC was associated with excellent survival rates, especially for HIV-negative BL. Further investigation of the predictive value of serum Rituximab levels is warranted.

Table 1. Rituximab Levels for Patients Without and With Disease Relapse.

Chemotherapy cycle/hours after R infusion	Median serum R level (ng/ml) for pts without relapse	Serum R level for 2 pts with relapse		Median CSF R level (ng/ml) for pts without relapse	CSF R levels for 2 pts with relapse	
		Pt #1	Pt #2		Pt #1	Pt #2
C1/24h	258,135	170,770	91,180	104	277	23
C1/72h	139,425	60,470	29,780	253	220	133
C3/24h	306,400	162,190	224,360	246	274	N/A
C3/72h	218,850	149,680	135,450	196	378	580

Abbreviations: C, cycle; h, hours; pt, patient; R, Rituximab.

Figure 1. Survival for High-Risk, HIV-Negative BL.

